



A MESSAGE FROM RENEE

For many of us, when the anniversary of the COVID pandemic came and went, we looked back and gave thought to just how much things had changed in the blink of an eye. Hugs and handshakes were exchanged for elbow bumps and eyebrow wrinkles. Get togethers took place on “Zoom” and “Facetime” as they became daily and indispensable communication tools that we now regularly use to keep in touch with family, friends, and colleagues



In light of our inability to meet in person, we have redoubled our efforts to bring our community the same high-quality programming and events as before, but in an all-virtual format. While it has been gratifying to be able to continue to enhance our patient and caregiver communication online, all of YES misses being able to see each other in person. There is no substitute for the hugs and warmth that we have shared in the past and I remain hopeful to return to in-person events in 2022.

It was a busy spring for the YES team. At the end of May, we held our first-ever virtual Ask the Experts event in which two leading liver tumor doctors answered questions from the more than 100 people who registered. The online format was very well received and we are grateful to have been able to address so many topics of interest for our all of you. We will continue to offer virtual events and programming in the coming months.

Remember, your donations make deLIVERing Hope possible. Please consider making a recurring monthly donation. Just \$10.00 will provide a Survivor Bag!

ONS DINNER IN ROGERS, ARKANSAS

On March 25th, Say YES to Hope had the opportunity to present at an Oncology Nursing Society dinner in Rogers, Arkansas with Kiley Korn of Sirtex Medical. It was wonderful to see all of the nurses and to share information alongside Methodist Hospital Oncology Nurse Navigator, Milka. Talking about living with Stage 4 colon cancer, about SIR-Spheres Microspheres and HOPE was humbling in front of such a powerful audience.



**NW ARKANSAS ONCOLOGY NURSES
SAY YES TO HOPE**

FIGHTING CANCER TAKES A TEAM!

Learning that you have liver cancer or that your cancer has spread (metastasized) to the liver is terrifying. Having a team approach is imperative....and must include YOU, a medical oncologist, a surgeon, an interventional radiologist, a radiation oncologist, and all those support people including friends and family, nurses, and a social worker.

It Takes a Team!!



Exciting news!!

Our friend and liver cancer survivor, Curtis Salgado, has been named 2021 Soul Blues Male Artist of the year! Chemo, SIR-Spheres, a liver transplant, and a dozen years of survivorship!



Keep On Keepin' On Corner

By Tami Thennis

“Optimism is the faith that leads to achievement. Nothing can be done without hope and confidence.”

- Helen Keller

“Sometimes when you least expect it, the tables turn and that very scary feeling that has taken hold of you for so long somehow turns into hope.”

- David Archuleta”

“Hope springs eternal.”

- J.K. Rowling

“Most of the things worth doing in the world were declared impossible before they were done.”

- Louis D. Brandels


“...and we'll see what happens when we say YES while this rigor mortis world screams No!”

- Isaac Marion

“Hope is the closest thing to a magic wand.”


- Suzanne Lindley





Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma

Researchers used The Cancer Genome Atlas database to develop a metastasis-related mRNAs prognostic model to improve the accuracy of prediction of hepatocellular carcinoma (HCC) prognosis. They used 374 HCC samples and 50 normal samples. From the HCMBD website, they obtained metastatic-related genes at the same time. Overall 1,895 metastasis-related mRNAs were screened and 6 mRNAs were identified to be related to prognosis. A significant stratification of HCC patients into high- and low-risk groups was enabled by overall survival (OS)-related prognostic model based on 5 MRGs (TPM1, SLC2A1, CDCA8, ATG10 and HOXD9). Experts also developed a nomogram which included the 5-gene signature and clinical features, for prognostic prediction. Overall, metastasis-related mRNAs prognostic model was corroborated to have a predictable value on the prognosis of HCC, which could assist for gene targeted therapy.



**Do you have inoperable liver tumors?
Have you heard of Y90?
Here is how it works.**

Selective Internal Radiation Therapy using SIR-Spheres® Y-90 resin microspheres enables radiation, which is often used to treat cancer, to be delivered directly into the liver tumors by using the tumor's own blood supply. Once injected, the microspheres are carried to the small blood vessels of the tumor where they lodge and emit radiation to kill the tumor cells.

(from the Sirtex Medical web-site)

OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it has entered into a Clinical Trial Collaboration and Supply Agreement ("Agreement") with Merck (known as MSD outside the United States and Canada) to evaluate the combination of OncoSec's DNA-plasmid interleukin-12 (IL-12) TAVO™ (tavokinogene telseplasmid) with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in a global Phase 3 randomized clinical trial, KEYNOTE-C87. The planned clinical trial will evaluate the overall survival of patients treated with the TAVO™ in combination with KEYTRUDA® versus standard of care in late-stage patients with metastatic melanoma who are refractory to immune checkpoint therapy.

TAVO™ has received Fast Track designation from the U.S. Food and Drug Administration (FDA), as a potentially first-in-class, intratumoral anti-cancer gene therapy that expresses IL-12 for the treatment of metastatic melanoma, following progression on KEYTRUDA® or OPDIVO® (nivolumab). KEYNOTE-C87 is intended to support accelerated approval by the U.S. FDA and/or serve as a pivotal study to support a full licensure. Under the terms of the Agreement, Merck will provide KEYTRUDA®, while OncoSec will provide the investigational drug, TAVO™. Each party will be responsible for its own internal costs, with OncoSec covering third party costs. Eligible patients must have Stage III or IV unresectable, metastatic melanoma, and must be refractory to prior checkpoint therapy. KEYNOTE-C87 intends to enroll approximately 400 patients and is planned to be conducted in the U.S., Canada, EU, and Australia.

NEWS TO USE



Toll Free SURVIVOR Line:

Our toll free Survivor Line provides an outlet for patients and concerned others. It is a place to access resources, advocacy, and support regarding treatment options for cancers of the liver. You can also receive information on how to become a part of our survivor support program, "FRIENDS for the Journey."

Call 1-877-937-7478



Survivor Support Program:

We offer a unique survivor mentoring program called "FRIENDS for the Journey" that matches survivors, caregivers, family and friends who are going through a similar experience. Comparing options is a vital way to maintain a positive outlook. FRIENDS can communicate via phone, email, snail mail, or in person.



YES! You Can Too

791 Arnold Paul * Canton, Texas 75103
877-937-7478

info@beatliver Tumors.org
www.beatliver Tumors.org